Table 3.
Multivariable logistic regression for predictors of infection within 1 year of immunomodulator use
| Characteristic | Odds Ratio | 95% confidence interval |
p-value |
|---|---|---|---|
| Age (for each1 year) | 1.01 | 1.00 – 1.01 | 0.16 |
| Sex | |||
| Male | 1.0 | Reference | |
| Female | 1.24 | 0.93 – 1.66 | 0.15 |
| Charlson comorbidity* | |||
| 0 | 1.0 | Reference | |
| ≥ 1 | 5.85 | 3.13 – 10.94 | < 0.0001 |
| Type of IBD | |||
| Ulcerative colitis | 1.0 | Reference | |
| Crohn’s disease | 0.96 | 0.71 – 1.29 | 0.78 |
| Concomitant medications | |||
| Anti-TNF therapy | |||
| No | 1.0 | Reference | |
| Yes | 1.14 | 0.80 – 1.63 | 0.46 |
| Corticosteroids | |||
| No | 1.0 | Reference | |
| Yes | 1.98 | 1.35 – 2.90 | < 0.001 |
| Diabetes | |||
| No | 1.0 | Reference | |
| Yes | 1.80 | 1.20 – 2.68 | 0.004 |
IBD – inflammatory bowel disease; Anti-TNF – monoclonal antibodies to tumor necrosis factor α (infliximab, adalimumab, certolizumab pegol)
*
Charlson index modified to exclude diabetes